Abstract
The outcome of patients with myeloma has improved significantly in the past decade with the incorporation of the immunomodulatory drugs thalidomide and lenalidomide and the proteasome inhibitor, bortezomib. Considering nearly all patients relapse, myeloma remains an active area of investigation. There are several promising classes of agents including next generation immunomodulatory agents, proteasome inhibitors, antibody and antitumor immunotherapy approaches that are being evaluated. This article provides an overview on the therapeutic strategies in the treatment of multiple myeloma.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 251-258 |
| Number of pages | 8 |
| Journal | Discovery Medicine |
| Volume | 15 |
| Issue number | 83 |
| State | Published - 2013 |
| Externally published | Yes |
ASJC Scopus subject areas
- General Medicine